LCH solely supplies various Grifols biological pharmaceutical products to hospitals, doctor clinics, and pharmacies. Products include Human Albumin, Rho(D) Immune Globulin, Hepatitis B, Rabies injections.
About Grifols products supplied by LCH
Luen Cheong Hong (LCH) Ltd, founded in 1940, is one of the leading pharmaceutical & medical supplies wholesale distributor in Hong Kong and Macau. In past 80 years, LCH has supplied Hong Kong and Macau with high quality medicine, injectables, healthcare products and medical supplies. LCH is currently one of the key suppliers for pharmaceuticals and medical supplies to all the public & private hospitals, doctors, pharmacies, restaurants, and five star hotel chains in Hong Kong and Macau.
Grifols products include:
GamaSTAN 2mL Immunoglobulin (Human) Injection
Hyperhep B 5mL Hepatitis B Immune Globulin (Human) Injection
Hyperhep B 0.5 ML 220IU/ML Prefilled Syringe Hepatitis B Immune Globulin (Human) Injection
Hyperrab 300IU/ML 1ml Rabies Immune Globulin (Human) Injection
Hyperrab 2 mL Rabies Immune Globulin (Human)
Rho(D) Hyperrho S/D Full Dose 1500IU Immune Globulin (Human)
Hypertet 250 Units 1 mL Tetanus Immune Globulin (Human)
Plasbumin 5% 250 mL Albumin (Human)
Plasbumin 25% 50 mL Albumin (Human) 12.5g
LCH is the sole distributor for all the products listed
Grifols is a global company that since 1909 has enhanced the health and well-being of people around the world. Our four divisions - Bioscience, Diagnostic, Hospital, and Bio Supplies - develop, produce, and market innovative solutions and services in more than 100 countries.
Grifols' origin lies in the laboratory founded in 1940 in Barcelona by Dr Josep A. Grífols Roig, a hematologist and scientist (although its origin dates back to the Instituto Central de Análisis Clínicos, a company founded in 1909 by Josep Antonio Grífols Roig, which will be a pioneer in Spain in clinical analysis and in the introduction of blood conservation and transfusion techniques). His son, Dr Josep A. Grifols Lucas was the first researcher to publish the plasmapheresis procedure in 1952. The company introduced its liquid IVIG product into the European market in the mid-1990s.
Probitas Pharma, S.A. was incorporated with high limited liability under Spanish law on 22 June 1987; on 27 June 2005 the company changed its name to Grifols, S.A. In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic (US subsidiary of Mitsubishi Pharma) as the basis of its American expansion. On May 17, 2006, Grifols securities were listed on Spain's Mercado Continuo.
In 2009, CSL Limited attempted to takeover Talecris Biotherapeutics (the former plasma business of Bayer HealthCare LLC, Biological Products Division) for $3,1 billion but was stopped by the Federal Trade Commission. On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.
Grifols acquired the blood transfusion diagnostics unit from Novartis in 2013 as a "platform for global expansion". This unit is based in Emeryville, California and was a part of Chiron acquired by Novartis in 2006.
In 2015, the company acquired a 45% stake in Alkahest as part of planned co-development of "plasma-based products for the treatment of cognitive decline in aging and disorders of the CNS, including Alzheimer's."In 2020 Grifols acquired the remaining stock of Alkahest “bringing its ownership of Alkahest to 100%”.
In December 2016, Grifols acquired Hologics interest in their existing joint blood screening unit for $1.85 billion.
The information on this website is intended for health care professionals only. Product information is for educational purposes only, and not all products or indications are licensed in every country. Product availability are subject to individual country license, rules, and regulations. The information on this website may not be reflecting the most updated information. Please contact directly for the most updated product information and availability.